Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pomaglumetad methionil

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

Eli Lilly HQ

Lilly eyes pivotal trials for pain drug tanezumab in 2015

Drug was placed under clinical hold by FDA in 2010

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

- PMLiVE

J&J gets quicker review for schizophrenia depot in US

Could be ready to market by the middle of this year

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

Lilly names head of corporate business development

Promotion for Darren Carroll

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

Eli Lilly HQ

Lilly signs $570m deal for next-gen Humalog

Licenses improved version of its insulin blockbuster from Adocia

Eli Lilly HQ

Lilly reports first pivotal data for Xeljanz rival in arthritis

Baricitinib on course for regulatory filing in late 2015

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links